Technical Analysis for NITE - Nightstar Therapeutics plc

Grade Last Price % Change Price Change
grade C 25.31 -0.16% -0.04
NITE closed down 0.16 percent on Tuesday, March 19, 2019, on 1.39 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Apr 2

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Flat
See historical NITE trend table...

Date Alert Name Type % Chg
Mar 1 200 DMA Resistance Bearish 66.95%
Mar 1 Calm After Storm Range Contraction 66.95%
Feb 28 20 DMA Support Bullish 70.78%
Feb 28 Slingshot Bullish Bullish Swing Setup 70.78%
Feb 28 Calm After Storm Range Contraction 70.78%
Feb 27 Bearish Engulfing Bearish 66.40%
Feb 27 Fell Below 200 DMA Bearish 66.40%
Feb 27 Slingshot Bullish Bullish Swing Setup 66.40%
Feb 27 Upper Bollinger Band Walk Strength 66.40%
Feb 27 Outside Day Range Expansion 66.40%

Older signals for NITE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Nightstar Therapeutics Limited is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company’s lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company’s third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Organ Systems Gene Therapy Ophthalmology Retinitis Pigmentosa Vision Blindness Retina X Linked Retinitis Pigmentosa Choroideremia
Is NITE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.545
52 Week Low 9.59
Average Volume 419,079
200-Day Moving Average 16.6231
50-Day Moving Average 16.7695
20-Day Moving Average 21.255
10-Day Moving Average 25.423
Average True Range 0.958
ADX 51.3
+DI 45.4971
-DI 9.002
Chandelier Exit (Long, 3 ATRs ) 23.006
Chandelier Exit (Short, 3 ATRs ) 16.794
Upper Bollinger Band 31.4319
Lower Bollinger Band 11.0781
Percent B (%b) 0.7
BandWidth 95.760056
MACD Line 2.9393
MACD Signal Line 2.7873
MACD Histogram 0.152
Fundamentals Value
Market Cap 711.24 Million
Num Shares 28.1 Million
EPS -0.65
Price-to-Earnings (P/E) Ratio -38.94
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.66
Resistance 3 (R3) 25.67 25.56 25.60
Resistance 2 (R2) 25.56 25.47 25.55 25.58
Resistance 1 (R1) 25.43 25.41 25.38 25.43 25.56
Pivot Point 25.33 25.33 25.30 25.32 25.33
Support 1 (S1) 25.20 25.24 25.15 25.19 25.06
Support 2 (S2) 25.09 25.18 25.09 25.04
Support 3 (S3) 24.97 25.09 25.02
Support 4 (S4) 24.96